<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01145079</url>
  </required_header>
  <id_info>
    <org_study_id>4-2009-0115</org_study_id>
    <nct_id>NCT01145079</nct_id>
  </id_info>
  <brief_title>A New Strategy Regarding Discontinuation of Dual Antiplatelet</brief_title>
  <official_title>A New Strategy Regarding Discontinuation of Dual Antiplatelet; Real Safety and Efficacy of a 3-month Dual Antiplatelet Therapy Following Zotarolimus-eluting Stents Implantation (RESET Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug-eluting stents (DES), markedly reducing the neointimal hyperplasia after stent&#xD;
      implantation compared with bare-metal stents (BMS), have improved angiographic and clinical&#xD;
      outcomes in the complex lesions and patients with high risks. However, currently, the fatal&#xD;
      events related with stent thrombosis still occur and are the major limitation of the use of&#xD;
      DES. Especially, late or very late thrombosis after DES implantation is an uncommon but&#xD;
      life-threatening fatal complication presented with sudden death or myocardial infarction (MI)&#xD;
      causing heart failure. The most powerful predictor for stent thrombosis is the&#xD;
      discontinuation of clopidogrel. In consideration of current data regarding stent thrombosis&#xD;
      and clinical situation of discontinuation of antiplatelet, zotarolimus-eluting stent (ZES)&#xD;
      [Endeavor®, Medtronic Vascular, Santa Rosa, CA] might be anticipated to be safer than other&#xD;
      DES during the long-term follow-up owing to healthy endothelialization. Endeavor® stent was&#xD;
      consists of zotarolimus, thin-strut, cobalt-chromium alloy stent platform (DriverTM stent;&#xD;
      Medtronic Vascular, Santa Rosa, CA), and phosphorylcholine coating. The ENDEAVOR II study&#xD;
      demonstrated clinically and statistically significant improvement in all of study endpoints,&#xD;
      including a 47 percent reduction in the primary endpoint of target vessel failure (TVF). In&#xD;
      addition, the ENDEAVOR II trial showed a 0.5 percent rate of stent thrombosis at 30 days -&#xD;
      with no late thrombosis beyond 30 days and no late stent malapposition. Because&#xD;
      reendothelialization after ZES implantation may occur within 3 months, 3-month dual&#xD;
      antiplatelet therapy is recommended in many clinical trials and real world practice. Shorter&#xD;
      maintenance of dual antiplatelet therapy might minimize the risk for stent thrombosis in&#xD;
      cases of discontinuation of antiplatelet and prevent waste medications and bleeding&#xD;
      complications related with dual antiplatelet therapy. However, there have been no&#xD;
      non-inferior or superior data of ZES considering all these circumstances. Therefore, the&#xD;
      investigators hypothesize that ZES with 3-month dual antiplatelet therapy may be safe and&#xD;
      beneficial in patients with coronary artery disease during follow-up than other DES, in spite&#xD;
      of higher late lumen loss. To test this hypothesis, the investigators will perform a&#xD;
      multi-center, randomized, prospective trial aimed at demonstrating the efficacy of the ZES&#xD;
      versus other DES in patients with coronary artery disease in real world practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome The composite of cardio-vascular death, MI, stent thrombosis, TVR and bleeding (minor or major) following randomly assigned DES implantation</measure>
    <time_frame>12 months after stent implantation</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">982</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Endeavor arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Endeavor resolute arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Xience arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cypher arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zotarolimus-eluting stent</intervention_name>
    <description>Zotarolimus-eluting stent</description>
    <arm_group_label>Endeavor arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zotarolimus-eluting stent for ACS and DM</intervention_name>
    <description>Zotarolimus-eluting stent for ACS and DM</description>
    <arm_group_label>Endeavor resolute arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Everolimus-eluting stent for long lesion</intervention_name>
    <description>Everolimus-eluting stent for long lesion</description>
    <arm_group_label>Xience arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sirolimus-eluting stent for short lesion</intervention_name>
    <description>Sirolimus-eluting stent for short lesion</description>
    <arm_group_label>Cypher arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Coronary artery disease including stable angina, unstable angina, acute non-ST&#xD;
             elevation myocardial infarction and acute ST elevation myocardial infarction&#xD;
&#xD;
          -  Age 20 years of older&#xD;
&#xD;
          -  Patients with typical chest pain or evidences of myocardial ischemia (e.g., stable,&#xD;
             unstable angina, silent ischemia and positive functional study or reversible changes&#xD;
             in the electrocardiogram (ECG) consistent with ischemia&#xD;
&#xD;
          -  Patients with signed informed consent&#xD;
&#xD;
          -  Lesion and stent length for ACS and DM subgroup : Length of single lesion &lt; 24 mm and,&#xD;
             Summation of total length of all inserted DES in 3 vessel &lt; 60 mm&#xD;
&#xD;
          -  Lesion and stent length for ACS and DM subgroup : Length of single lesion &lt; 24 mm and,&#xD;
             Summation of total length of all inserted DES in 3 vessel &lt; 60 mm&#xD;
&#xD;
          -  Lesion and stent length for long lesion subgroup : Length of single stent per single&#xD;
             lesion &gt; 28 mm and, Summation of total length of all inserted DES in 3 vessel ≤ 90 mm,&#xD;
             Possible overlapping stent&#xD;
&#xD;
          -  Lesion and stent length for short lesion subgroup : Length of single lesion &lt; 24 mm&#xD;
             and, Summation of total length of all inserted DES in 3 vessel &lt; 60 mm&#xD;
&#xD;
          -  Significant coronary artery stenosis (&gt;50% by visual estimate) considered for coronary&#xD;
             revascularization with stent implantation&#xD;
&#xD;
          -  Reference vessel diameter of 2.5 to 4.0 mm by operator assessment&#xD;
&#xD;
          -  Lesion success (30% or less residual stenosis by visual assessment over the entire&#xD;
             stent length, with TIMI-3 flow and no more than an NHLBI type B peri-stent dissection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to anti-platelet agents &amp; bleeding history within prior 3 months&#xD;
&#xD;
          -  Known hypersensitivity or contraindication to any of the following medications:&#xD;
             Heparin, Aspirin, Clopidogrel, limus related drug&#xD;
&#xD;
          -  Prior history of the following presentations : Cerebral vascular accident (not&#xD;
             including transient ischemic attack, Peripheral artery occlusive diseases,&#xD;
             Thromboembolic disease, Stent thrombosis&#xD;
&#xD;
          -  Severe hepatic dysfunction (3 times normal reference values)&#xD;
&#xD;
          -  Significant renal dysfunction (Serum creatinine &gt; 2.0 mg/dl)&#xD;
&#xD;
          -  Significant leukopenia, neutropenia, thrombocytopenia, anemia, or known bleeding&#xD;
             diathesis&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  LVEF &lt; 40%&#xD;
&#xD;
          -  Pregnant women or women with potential childbearing&#xD;
&#xD;
          -  Life expectancy 3 year&#xD;
&#xD;
          -  Overlapped DESs(only long lesion subgroup is possible overlapping)&#xD;
&#xD;
          -  Left main disease requiring PCI&#xD;
&#xD;
          -  Bifurcation lesion with 2-stent technique&#xD;
&#xD;
          -  Target lesions with in-stent restenosis at the stented segment of DES or BMS&#xD;
&#xD;
          -  Lesions with chronic total occlusion&#xD;
&#xD;
          -  History of PCI with DES&#xD;
&#xD;
          -  In-stent restenosis lesion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myeong Ki Hong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Cardiovascular Hospital, Yonsei University College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Severance Cardiovascular Hospital, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>June 14, 2010</study_first_submitted>
  <study_first_submitted_qc>June 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2010</study_first_posted>
  <last_update_submitted>March 4, 2013</last_update_submitted>
  <last_update_submitted_qc>March 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

